United States News All stories

BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.

ASE Technology Holding (NYSE:ASX) reported unaudited consolidated net revenues of NT$82.25 billion for August 2026, increasing 45.7% year over year and 11.5% from July 2026.

Evotec (NASDAQ:EVO) initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses developed by its Just – Evotec Biologics subsidiary.

State Street Corporation (NYSE:STT) has named its Australia country head, Tim Helyar, as the new head of Asia Pacific.

WaFd (NASDAQ:WAFD) agreed to merge with EverBank Financial Corp in a $3.9 billion transaction that will combine the Seattle-based regional lender with the Jacksonville-based online bank.

Qualcomm (NASDAQ:QCOM) announced a multi-generation partnership with Amazon Web Services to develop custom AI data center chips, expanding its role in artificial intelligence infrastructure.

Cresud (NASDAQ:CRESY) reported FY 2026 net income of ARS 372,280 million for the year ended June 30, 2026, compared with ARS 299,635 million in FY 2025.

GameStop (NYSE:GME) reported a second-quarter operating income of $160.2 million driven by a 57% year-over-year increase in collectibles sales.

Quantum Cyber (NASDAQ:QUCY) acquired a Lambda Hyperplane 8-A100 AI compute cluster powered by NVIDIA A100 Tensor Core GPUs to support its autonomous defense platforms and AI development efforts.

BioVie (NASDAQ:BIVI) advanced regulatory discussions with the U.S. FDA for a Phase 3 development program evaluating bezisterim in Parkinson’s disease following Phase 2 SUNRISE-PD results.

GE Aerospace (NYSE:GE) agreed to acquire Consolidated Precision Products (CPP) for $11.75 billion, expanding its aerospace casting capabilities for commercial aviation, defense, and power markets.

AEVEX Corp. (NYSE:AVEX) completed its acquisition of BlackSea Technologies, adding unmanned surface and subsea vessel capabilities to its autonomous defense systems business.

Inhibrx Biosciences (NASDAQ:INBX) reported Phase 2 HexAgon trial results showing INBRX-106 combined with pembrolizumab achieved a 48.3% confirmed objective response rate in first-line head and neck cancer patients.

Abbott (NYSE:ABT) received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat atrial fibrillation using pulsed field ablation and radiofrequency energy technologies.

AstraZeneca (NASDAQ:AZN) reported Phase III OBERON and TITANIA trial results showing tozorakimab reduced moderate and severe COPD exacerbations across broad patient populations while patients remained on standard inhaled treatment.

enGene Therapeutics (NASDAQ:ENGN) reported regulatory and clinical progress for detalimogene, including plans for a U.S. FDA pre-BLA meeting and initiation of a Biologics License Application submission in the fourth quarter of 2026.

IonQ (NYSE:IONQ) expects full-year 2026 revenue of $450 million–$460 million following its acquisition of SkyWater Technology, with the outlook including SkyWater’s contribution from July 31 through December 31, 2026.

Adlai Nortye (NASDAQ:ANL) dosed the first patient in Australia in a global Phase I trial evaluating AN4035, an antibody-drug conjugate designed to treat CEACAM5-enriched RAS-addicted solid tumors.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel) in adults with quadruple-class exposed relapsed and refractory multiple myeloma.

United Natural Foods (NYSE:UNFI) reported fiscal 2026 net sales of $31.2 billion, down 2% year over year, while adjusted EBITDA increased 27% to $701 million.

ABM (NYSE:ABM) reported fiscal third-quarter 2026 revenue of $2.32 billion, up 4.2% year over year, with net income rising to $49.7 million from $41.8 million in the prior-year period.

Pharvaris (NASDAQ:PHVS) reported Phase 3 CHAPTER-3 results showing once-daily oral deucrictibant XR reduced hereditary angioedema attack rates by 83% versus placebo across all HAE types after 24 weeks.

Bullish (NYSE:BLSH) reported August 2026 trading metrics showing total trading volume of $42.5 billion, up from July 2026 but below the same month in 2025.

Solaris Energy Infrastructure (NASDAQ:SEI) raised its fourth-quarter 2026 adjusted EBITDA guidance to $145 million–$180 million as the company expands power infrastructure to support rising electricity demand from data centers.